Pharmacokinetics, Safety, and Clinical Efficacy of Cannabidiol Treatment in Osteoarthritic Dogs
Pharmacokinetics, Safety, and Clinical Efficacy of Cannabidiol Treatment in Osteoarthritic Dogs
复制标题
DOI：
10.3389/fvets.2018.00165
复制
发表时间：
2018-07-23
影响因子：
3.2
通讯作者：
Wakshlag, Joseph J.
中科院分区：
文献类型：
--
作者：
Gamble, Lauri-Jo;Boesch, Jordyn M.;Wakshlag, Joseph J.
目的：本研究的目的是确定基本的口服药代动力学，并评估基于大麻二酚（CBD）的油在患有骨关节炎（OA）的狗中的安全性和镇痛功效。方法：使用两种不同剂量的富含大麻二酚（CBD）的油进行单剂量药代动力学（2和8 mg/kg））。此后，进行了一项随机、安慰剂对照、兽医和主人设盲、交叉研究。狗接受两种治疗：CBD油（2 mg/kg）或安慰剂油，每12小时一次。每次治疗持续4周，其中有2周的洗脱期。在开始每次给药前以及第2周和第4周完成基线兽医评估和主人问卷调查。在每次访视时进行血液学、血清化学和体格检查。采用混合模型分析，分析所有其他时间点相对于入组基线的变化，用于所有感兴趣的变量，p
Objectives: The objectives of this study were to determine basic oral pharmacokinetics, and assess safety and analgesic efficacy of a cannabidiol (CBD) based oil in dogs with osteoarthritis (OA).Methods: Single-dose pharmacokinetics was performed using two different doses of CBD enriched (2 and 8 mg/kg) oil. Thereafter, a randomized placebo-controlled, veterinarian, and owner blinded, cross-over study was conducted. Dogs received each of two treatments: CBD oil (2 mg/kg) or placebo oil every 12 h. Each treatment lasted for 4 weeks with a 2-week washout period. Baseline veterinary assessment and owner questionnaires were completed before initiating each treatment and at weeks 2 and 4. Hematology, serum chemistry and physical examinations were performed at each visit. A mixed model analysis, analyzing the change from enrollment baseline for all other time points was utilized for all variables of interest, with a p